Study of Bafetinib as Treatment for Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL)



Status:Archived
Conditions:Blood Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:Any
Updated:7/1/2011
Start Date:June 2010
End Date:April 2012

Use our guide to learn which trials are right for you!

A Pilot Phase II Study of Bafetinib (INNO-406) as Treatment for Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL)


A Study of Bafetinib as Treatment for Patients with Relapsed or Refractory B-Cell Chronic
Lymphocytic Leukemia (B-CLL).


Bafetinib is a dual protein kinase inhibitor, targeting both bcr/abl and Lyn kinases. B-cell
chronic lymphocytic leukemia cells overexpress Lyn kinase compared to normal B lymphocytes
as well as acute leukemias (ALL and AML), and inhibition of Lyn kinase induces apoptosis in
cultures of B-CLL cells. Thus, bafetinib may stop the growth of B-CLL cells by inhibiting
Lyn kinase, the molecule that couples the B cell receptor to downstream signaling.


We found this trial at
3
sites
1515 Holcombe Blvd
Houston, Texas 77030
 713-792-2121
University of Texas M.D. Anderson Cancer Center The mission of The University of Texas MD...
?
mi
from
Houston, TX
Click here to add this to my saved trials
Duarte, California 91010
?
mi
from
Duarte, CA
Click here to add this to my saved trials
100 NE Loop 410; Suite 600
San Antonio, Texas 78216
210-424-1600
Cancer Care Centers of South Texas At Cancer Care Centers of South Texas, we are...
?
mi
from
San Antonio, TX
Click here to add this to my saved trials